Akebia Therapeutics, Inc. (AKBA) stock
AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.45−0.03 (-5.40%)
Close on Nov 16, 2026Market cap $124.31MP/E –Yield –
Akebia Therapeutics cash
Cash and short-term investments held at the end of each period.
Akebia Therapeutics's cash was $155.55M at Jun 30, 2026. For fiscal 2025 it was $184.84M, up 245.2% from the year before. Over ten years it grew 2.9% a year on average. The highest annual figure on record is $321.64M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.84M | +245.2% |
| FY2024 | Dec 31, 2024 | $53.55M | +24.8% |
| FY2023 | Dec 31, 2023 | $42.93M | -53.9% |
| FY2022 | Dec 31, 2022 | $93.17M | -37.8% |
| FY2021 | Dec 31, 2021 | $149.80M | -44.2% |
| FY2020 | Dec 31, 2020 | $268.69M | +81.9% |
| FY2019 | Dec 31, 2019 | $147.69M | -54.1% |
| FY2018 | Dec 31, 2018 | $321.64M | +1.2% |
| FY2017 | Dec 31, 2017 | $317.79M | +22.1% |
| FY2016 | Dec 31, 2016 | $260.34M | +87.7% |
| FY2015 | Dec 31, 2015 | $138.69M | +27.3% |
| FY2014 | Dec 31, 2014 | $108.97M | +234.7% |
| FY2013 | Dec 31, 2013 | $32.55M | +1883.8% |
| FY2012 | Dec 31, 2012 | $1.64M | -67.3% |
| FY2011 | Dec 31, 2011 | $5.01M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $155.55M | +11.9% |
| Q1 FY2026 | Mar 31, 2026 | $162.64M | +41.4% |
| Q4 FY2025 | Dec 31, 2025 | $184.84M | +245.2% |
| Q3 FY2025 | Sep 30, 2025 | $166.44M | +366.3% |
| Q2 FY2025 | Jun 30, 2025 | $139.00M | +237.6% |
| Q1 FY2025 | Mar 31, 2025 | $115.06M | +163.8% |
| Q4 FY2024 | Dec 31, 2024 | $53.55M | +24.8% |
| Q3 FY2024 | Sep 30, 2024 | $35.69M | -25.9% |
| Q2 FY2024 | Jun 30, 2024 | $41.17M | -25.5% |
| Q1 FY2024 | Mar 31, 2024 | $43.62M | -26.9% |
| Q4 FY2023 | Dec 31, 2023 | $42.93M | -53.9% |
| Q3 FY2023 | Sep 30, 2023 | $48.18M | -67.4% |
| Q2 FY2023 | Jun 30, 2023 | $55.29M | -62.4% |
| Q1 FY2023 | Mar 31, 2023 | $59.67M | -66.4% |
| Q4 FY2022 | Dec 31, 2022 | $93.17M | -37.8% |
| Q3 FY2022 | Sep 30, 2022 | $147.85M | -28.6% |
| Q2 FY2022 | Jun 30, 2022 | $146.98M | -40.5% |
| Q1 FY2022 | Mar 31, 2022 | $177.65M | -34.9% |
| Q4 FY2021 | Dec 31, 2021 | $149.80M | -44.2% |
| Q3 FY2021 | Sep 30, 2021 | $207.20M | -23.0% |
| Q2 FY2021 | Jun 30, 2021 | $246.99M | -16.4% |
| Q1 FY2021 | Mar 31, 2021 | $272.76M | +136.4% |
| Q4 FY2020 | Dec 31, 2020 | $268.69M | +81.9% |
| Q3 FY2020 | Sep 30, 2020 | $269.26M | +84.9% |
| Q2 FY2020 | Jun 30, 2020 | $295.35M | +116.0% |
| Q1 FY2020 | Mar 31, 2020 | $115.37M | -31.3% |
| Q4 FY2019 | Dec 31, 2019 | $147.69M | -54.1% |
| Q3 FY2019 | Sep 30, 2019 | $145.61M | -62.7% |
| Q2 FY2019 | Jun 30, 2019 | $136.77M | -66.0% |
| Q1 FY2019 | Mar 31, 2019 | $168.04M | -57.2% |
| Q4 FY2018 | Dec 31, 2018 | $321.64M | +1.2% |
| Q3 FY2018 | Sep 30, 2018 | $390.14M | +18.3% |
| Q2 FY2018 | Jun 30, 2018 | $402.12M | +25.1% |
| Q1 FY2018 | Mar 31, 2018 | $393.03M | +56.0% |
| Q4 FY2017 | Dec 31, 2017 | $317.79M | +22.1% |
| Q3 FY2017 | Sep 30, 2017 | $329.89M | +104.5% |
| Q2 FY2017 | Jun 30, 2017 | $321.47M | – |
| Q1 FY2017 | Mar 31, 2017 | $251.98M | – |
| Q4 FY2016 | Dec 31, 2016 | $260.34M | – |
| Q3 FY2016 | Sep 30, 2016 | $161.33M | – |
See a number that looks wrong?